Potent antitumour activity of the combination of HSV-TK and endostatin armed oncolytic adeno-associated virus for bladder cancer in vitro and in vivo

Journal of Surgical Oncology

Volumn 105, Issue 3, 2012, Pages 249-257

  Pan, Jian Gang ^a   Zhou, Xing ^a   Zeng, Ge Wa ^a   Han, Rui Fa ^b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

bladder tumour; cancer gene therapy; Endostatin; HSV thymidine kinase

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALIPOGENE TIPARVOVEC; ENDOSTATIN; ONCOLYTIC ADENOVIRUS; SITIMAGENE CERADENOVEC; TIE 1 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC GENE THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOTOXICITY; ERADICATION THERAPY; GENE INSERTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; TUMOR CELL; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DEPENDOVIRUS; ENDOSTATINS; GENE THERAPY; GENETIC VECTORS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSFECTION; URINARY BLADDER NEOPLASMS;

EID: 84856290181     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22107     Document Type: Article

References (22)

1. Cross D, Burmester JK,: Gene therapy for cancer treatment: Past, present and future. Clin Med Res 2006; 4: 218-227. (Pubitemid 44496015)
2. Seth P,: Vector-mediated cancer gene therapy: An overview. Cancer Biol Ther 2005; 4: 512-517. (Pubitemid 41351222)
3. Persano L, Crescenzi M, Indraccolo S,: Anti-angiogenic gene therapy of cancer: Current status and future prospects. Mol Aspects Med 2007; 28: 87-114.
4. Shi W, Teschendorf C, Muzyczka N, et al.: Gene therapy delivery of Endostatin enhances the treatment efficacy of radiation. Radiother Oncol 2003; 66: 1-9. (Pubitemid 36135998)
5. Folkman J,: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
6. Nguyen JT, Wu P, Clouse ME, et al.: Adenoassociated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res 2008; 58: 5673-5677.
7. Fillat C, Carrio M, Cascante A, et al.: Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: Fifteen years of application. Curr Gene Ther 2003; 3: 13-26.
8. Kagawa S, He C, Gu J, et al.: Antitumour activity and bystander effects of the tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001; 61: 3330-3338. (Pubitemid 32695022)
9. Qiao J, Black ME, Caruso M,: Enhanced ganciclovir killing and bystander effect of human tumour cells transduced with a retroviral vector carrying a herpes simplex virus thymidine kinase gene mutant. Hum Gene Ther 2000; 11: 1569-1576. (Pubitemid 30670608)
10. Ma H, Liu Y, Liu S,: Recombinant adenoassociated virus-mediated TRAIL gene therapy suppresses liver metastatic tumours. Int J Cancer 2005; 116: 314-321. (Pubitemid 40967271)
11. Shi J, Zheng D, Liu Y,: Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumour xenografts in nude mice. Cancer Res 2005; 65: 1687-1692. (Pubitemid 40478593)
12. Pan JG, Zhou X, Zeng GW, et al.: Suppression of bladder cancer growth in mice by adeno-associated virus vector-mediated endostatin expression. Tumor Biol 2011; 32: 301-310.
13. AAV Helper-Free System Instruction Manual. Revision A.02.
14. Wu X, Dong X, Wu Z, et al.: A novel method for purification of recombinant adenoassociated virus vectors on a large scale. Chin Sci Bull 2001; 6: 485-490.
15. Chen QR, Kumar D, Stass SA, et al.: Liposomes complexed to plasmids encoding angiostatin and Endostatin inhibit breast cancer in nude mice. Cancer Res 1999; 59: 3308-3312. (Pubitemid 29334481)
16. Szary J, Szala S,: Intra-tumoural administration of naked plasmid DNA encoding mouse Endostatin inhibits renal carcinoma growth. Int J Cancer 2001; 91: 835-839. (Pubitemid 32178653)
17. Joki T, Machluf M, Atala A, et al.: Continuous release of Endostatin from microencapsulated engineered cells for tumour therapy. Nat Biotechnol 2001; 19: 35-39. (Pubitemid 32051953)
18. Feldman AL, Restifo NP, Alexander HR, et al.: Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic Endostatin levels in mice. Cancer Res 2000; 60: 1503-1506. (Pubitemid 30183414)
19. Sauter BV, Martinet O, Zhang WJ, et al.: Adenovirus mediated gene transfer of Endostatin in vivo results in high level of transgene expression and inhibition of tumour growth and metastases. Proc Natl Acad Sci USA 2000; 97: 4802-4807. (Pubitemid 30238638)
20. Wu Z, Asokan A, Samulski RJ,: Adeno-associated virus serotypes: Vector tool kit for human gene therapy. Mol Ther 2006; 14: 316-327. (Pubitemid 44184972)
21. Xiao X, Li J, Samulski RJ,: Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associate virus vector. J Virol 2009; 70: 8098-8108.
22. Kyoko H, Lee J, Yoshie M, et al.: The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy. J Gen Med 2006; 8: 1056-1067. (Pubitemid 44283002)